SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 2, 2003
Anika Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Massachusetts |
|
000-21326 |
|
04-3145961 |
|
(State or
Other Jurisdiction of |
|
(Commission
file |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
160 New Boston Street, Woburn, Massachusetts |
|
01801 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
|
|
|
|
||
|
Registrant’s Telephone Number, Including Area Code: (781) 932-6616 |
||||
Item 5: Other Events and Required FD Disclosure.
On December 2, 2003, Anika Therapeutics, Inc. issued a press release (“Press Release”) announcing that it had received an approvable letter from the U.S. Food and Drug Administration regarding its ORTHOVISCÒ osteoarthritis product. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.
Item 7: Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release issued by Anika Therapeutics, Inc. on December 2, 2003 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
ANIKA THERAPEUTICS, INC. |
||
|
|
|
||
|
December 2, 2003 |
By: |
/s/ Charles H. Sherwood |
|
|
|
|
Charles H. Sherwood, Ph.D. |
|
|
|
|
Chief Executive Officer and President |
|
3
Exhibit Index
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release of Anika Therapeutics, Inc. dated December 2, 2003 |
4